Structural Formula Gemcitabine (Gemcitabine 01)
Gemcitabine Injection, Powder, Lyophilized, For Solution
Product Images NDC 0409-0187
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Gemcitabine (NDC 0409-0187). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Hospira, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1: Kaplan-meier Curve Of Progression Free Survival In Gemcitabine Plus Carboplatin Versus Carboplatin In Ovarian Cancer (Gemcitabine 02)
This is a graph showing the progression-free probability of Gemcitabine/Carboplatin versus Carboplatin alone in a sample of 178 patients. The x-axis shows the progression-free survival in months, while the y-axis shows the probability of remaining progression-free. Gemcitabine/Carboplatin showed a statistically significant benefit compared to Carboplatin alone.*
Figure 2: Kaplan-meier Curve Of Time To Documented Disease Progression In Gemcitabine Plus Paclitaxel Versus Paclitaxel Breast Cancer Study (Gemcitabine 03)
This is a medical document comparing the progression-free probability and median time to disease progression for two treatments: Gemcitabine / Paclitaxel and Paclitaxel alone. The text includes statistical data such as the number of participants in each treatment group, the log rank p-value and the median time to disease progression in months.*
Xen-1822-4figure 3: Kaplan-meier Survival Curve In Gemcitabine Plus Cisplatin Versus Cisplatin Nsclc Study (Gemcitabine 04)
Figure 4: Kaplan-meier Survival Curve (Gemcitabine 05)
This seems to be a graph or chart displaying the fraction surviving over a period of time (in months) for two cancer treatments: Gemcitabine and 5-FU. The vertical axis represents the fraction surviving (ranging from 0.0 to 1.0). The horizontal axis shows the survival time in months (ranging from 4 to 20 months). The graph appears to compare the effectiveness of both treatments in treating cancer over time.*
Hospira Logo (Gemcitabine 06)
Principal Display Panel (2 g Vial Label)
Gemcitabine for Injection, USP is a cytotoxic agent that is available as a 2 g single-dose vial for intravenous use only. The vial is sterile and has an unvarnished area. The product is lyophilized, and caution should be taken when using it. The text also includes various other alphanumeric codes that are difficult to interpret.*
Principal Display Panel (2 g Vial Carton)
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
